|
Fig. S1
tcf21:CreER does not label cardiomyocytes or precursors of cardiomyocytes in the β-act2:RSG muscle indicator background. (A,B) Robust cardiomyocyte labeling (green) of adult ventricles and atria of cmlc2:CreER; β-act2:RSG animals treated as larvae with 4-hydroxytamoxifen (4-HT). (C,D) Ventricles and atria of adult tcf21:CreER; β-act2:RSG treated as larvae with 4-HT display no cardiomyocyte enhanced green fluorescent protein (EGFP) labeling. (E,F) 30 days post-amputation (dpa) regenerates (brackets) from cmlc2:CreER; β-act2:RSG (E) or tcf21:CreER; β-act2:RSG (F) animals that were treated with 4-HT at larval stages, assessed for cardiomyocyte EGFP labeling (n=6). (G) No cardiomyocyte EGFP labeling was observed in 30 dpa regenerates (brackets) of tcf21:CreER; β-act2:RSG that underwent 4-HT labeling as adults (n=4). Dashed lines indicate approximate amputation planes. at, atrium; ve, ventricle. Scale bars: 50 μm.